{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:42:47Z","timestamp":1793148167233,"version":"4.5.0"},"reference-count":43,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2024,3,20]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pivotal phase 3 trials and real-world studies have demonstrated benralizumab's overall efficacy and safety in severe eosinophilic asthma (SEA). Additional large-cohort data are needed to confirm its real-world effectiveness in SEA according to previous biologic use and key baseline characteristics important for treatment selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>XALOC-1 is a large, multinational, retrospective, observational, real-world study programme of benralizumab in adults with SEA. This 48-week integrated analysis assessed annualised exacerbation rate (AER), maintenance oral corticosteroid (mOCS) use, asthma symptom control and lung function during a 12-month baseline period and up to 48\u2005weeks after benralizumab initiation. Subgroup analyses were based on previous biologic use and key baseline clinical characteristics (mOCS use, blood eosinophil count, exacerbation history, age at asthma diagnosis, fractional exhaled nitric oxide level and presence of atopy and chronic rhinosinusitis with nasal polyps).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of 1002 patients analysed, 380 were biologic-experienced. At week 48, 71.3% were exacerbation-free (\n                      <jats:italic>versus<\/jats:italic>\n                      17.2% at baseline); relative reduction in AER was 82.7% overall and 72.9% in biologic-experienced patients; rates were maintained across all key clinical characteristic subgroups. Of patients using mOCS at baseline (n=274), 47.4% (130 out of 274) eliminated their use by week 48; the mean reduction from baseline in daily dose was 51.2% and, notably, 34.9% in biologic-experienced patients (n=115). Clinically significant improvements in asthma symptom control and lung function were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this large, real-world programme, SEA patients treated with benralizumab had substantial improvements in clinical outcomes irrespective of previous biologic use and key clinical characteristics important to therapeutic decision-making in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.01521-2023","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T11:30:12Z","timestamp":1712230212000},"page":"2301521","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":59,"title":["Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme"],"prefix":"10.1183","volume":"64","author":[{"given":"David J.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolamo","family":"Pelaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Emmanuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trung N.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-4210","authenticated-orcid":false,"given":"Vivian H.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Shavit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Arbetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Katial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5237-0677","authenticated-orcid":false,"given":"Adrian Paul J.","family":"Rabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Garcia Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Pardal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Nuevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Boarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Kayaniyil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0438-6126","authenticated-orcid":false,"given":"Cl\u00e1udia","family":"Chaves Loureiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Padilla-Galo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"2024102103251586000_64.1.2301521.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.042"},{"key":"2024102103251586000_64.1.2301521.2","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"2024102103251586000_64.1.2301521.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03393-2020"},{"key":"2024102103251586000_64.1.2301521.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.04.004"},{"key":"2024102103251586000_64.1.2301521.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202003-0729LE"},{"key":"2024102103251586000_64.1.2301521.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"2024102103251586000_64.1.2301521.7","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"2024102103251586000_64.1.2301521.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"2024102103251586000_64.1.2301521.9","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5 years","volume":"9","author":"Korn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102103251586000_64.1.2301521.10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JAA.S328653","article-title":"Real world biologic use and switch patterns in severe asthma: data from the International Severe Asthma Registry and the US CHRONICLE study","volume":"15","author":"Menzies-Gow","year":"2022","journal-title":"J Asthma Allergy"},{"key":"2024102103251586000_64.1.2301521.11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.anai.2021.03.015","article-title":"Clinical and economic burden of severe asthma among US patients treated with biologic therapies","volume":"127","author":"Reibman","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2024102103251586000_64.1.2301521.12","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jaip.2022.02.014","article-title":"Benralizumab effectiveness in severe asthma is independent of previous biologic use","volume":"10","author":"Jackson","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102103251586000_64.1.2301521.13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-022-01952-8","article-title":"ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study","volume":"23","author":"Menzella","year":"2022","journal-title":"Respir Res"},{"key":"2024102103251586000_64.1.2301521.14","unstructured":"AstraZeneca . Fasenra. Summary of Product Characteristics. 2022. www.ema.europa.eu\/en\/documents\/product-information\/fasenra-epar-product-information_en.pdf"},{"key":"2024102103251586000_64.1.2301521.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.09.008"},{"key":"2024102103251586000_64.1.2301521.16","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.1999.14d29.x"},{"key":"2024102103251586000_64.1.2301521.17","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01514"},{"key":"2024102103251586000_64.1.2301521.18","doi-asserted-by":"crossref","first-page":"4839230","DOI":"10.1155\/2018\/4839230","article-title":"Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma","volume":"2018","author":"Pelaia","year":"2018","journal-title":"Biomed Res Int"},{"key":"2024102103251586000_64.1.2301521.19","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jaci.2018.01.008","article-title":"Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma","volume":"141","author":"Sehmi","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2024102103251586000_64.1.2301521.20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/cea.12695","article-title":"Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma","volume":"46","author":"Sehmi","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"2024102103251586000_64.1.2301521.21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13223-020-00507-0","article-title":"Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts","volume":"17","author":"Ghassemian","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2024102103251586000_64.1.2301521.22","doi-asserted-by":"crossref","first-page":"105819","DOI":"10.1016\/j.rmed.2019.105819","article-title":"Eosinophils, the IL-5\/IL-5R\u03b1 axis, and the biologic effects of benralizumab in severe asthma","volume":"160","author":"Matucci","year":"2019","journal-title":"Respir Med"},{"key":"2024102103251586000_64.1.2301521.23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200208-789OC"},{"key":"2024102103251586000_64.1.2301521.24","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S2213-2600(21)00004-7","article-title":"The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study","volume":"9","author":"McDowell","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102103251586000_64.1.2301521.25","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/all.13850","article-title":"The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma","volume":"74","author":"Chapman","year":"2019","journal-title":"Allergy"},{"key":"2024102103251586000_64.1.2301521.26","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s12325-019-01191-2","article-title":"Ability of serum IgE concentration to predict exacerbation risk and benralizumab efficacy for patients with severe eosinophilic asthma","volume":"37","author":"Jackson","year":"2020","journal-title":"Adv Ther"},{"key":"2024102103251586000_64.1.2301521.27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00166-2021"},{"key":"2024102103251586000_64.1.2301521.28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00936-2018"},{"key":"2024102103251586000_64.1.2301521.29","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102103251586000_64.1.2301521.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.02.039"},{"key":"2024102103251586000_64.1.2301521.31","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.jaip.2021.01.008","article-title":"The relationship between FeNO and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma","volume":"9","author":"Hearn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102103251586000_64.1.2301521.32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jaci.2023.03.023","article-title":"Eosinophils promote effector functions of lung group 2 innate lymphoid cells in allergic airway inflammation in mice","volume":"152","author":"LeSuer","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2024102103251586000_64.1.2301521.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.08.2083"},{"key":"2024102103251586000_64.1.2301521.34","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215168"},{"key":"2024102103251586000_64.1.2301521.35","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.2147\/JAA.S377174","article-title":"Characterization of patients in the International Severe Asthma Registry with high steroid exposure who did or did not initiate biologic therapy","volume":"15","author":"Chen","year":"2022","journal-title":"J Asthma Allergy"},{"key":"2024102103251586000_64.1.2301521.36","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207630"},{"key":"2024102103251586000_64.1.2301521.37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"key":"2024102103251586000_64.1.2301521.38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024102103251586000_64.1.2301521.39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/JAA.S297273","article-title":"Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: real-life evaluation correlated with allergic and non-allergic phenotype expression","volume":"14","author":"Pelaia","year":"2021","journal-title":"J Asthma Allergy"},{"key":"2024102103251586000_64.1.2301521.40","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2147\/JAA.S319572","article-title":"Real-world multicenter experience with mepolizumab and benralizumab in the treatment of uncontrolled severe eosinophilic asthma over 12 months","volume":"14","author":"Kayser","year":"2021","journal-title":"J Asthma Allergy"},{"key":"2024102103251586000_64.1.2301521.41","doi-asserted-by":"crossref","first-page":"100600","DOI":"10.1016\/j.waojou.2021.100600","article-title":"Real-world benefits of biologics for asthma: exacerbation events and systemic corticosteroid use","volume":"14","author":"Kimura","year":"2021","journal-title":"World Allergy Organ J"},{"key":"2024102103251586000_64.1.2301521.42","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12890-020-01220-9","article-title":"Real-life experience with benralizumab during 6\u2005months","volume":"20","author":"Padilla-Galo","year":"2020","journal-title":"BMC Pulm Med"},{"key":"2024102103251586000_64.1.2301521.43","doi-asserted-by":"crossref","first-page":"950883","DOI":"10.3389\/fmed.2022.950883","article-title":"Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: an ANANKE study post hoc analysis","volume":"9","author":"Caruso","year":"2022","journal-title":"Front Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01521-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T02:20:01Z","timestamp":1740363601000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01521-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7,11]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1183\/13993003.01521-2023"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01521-2023","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]}}}